Morgan Stanley Rezolute, Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Rezolute, Inc. stock. As of the latest transaction made, Morgan Stanley holds 54,948 shares of RZLT stock, worth $218,693. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,948
Previous 79,029
30.47%
Holding current value
$218,693
Previous $383,000
31.59%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding RZLT
# of Institutions
76Shares Held
44.6MCall Options Held
201KPut Options Held
2.8K-
Federated Hermes, Inc. Pittsburgh, PA11.3MShares$44.9 Million0.13% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.86MShares$11.4 Million0.69% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.8MShares$11.1 Million2.6% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$10.1 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.32MShares$9.24 Million0.0% of portfolio
About Rezolute, Inc.
- Ticker RZLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,600
- Market Cap $155M
- Description
- Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...